Risk factors for lower limb lymphedema in gynecologic cancer patients after initial treatment

Teruyo Kunitake\textsuperscript{1,2} \cdot Tatsuyuki Kakuma\textsuperscript{3} \cdot Kimio Ushijima\textsuperscript{4}

Received: 25 June 2019 / Accepted: 17 December 2019 / Published online: 6 January 2020
© The Author(s) 2020

Abstract
Background Most studies on lower limb lymphedema have been conducted in gynecologic cancer patients who underwent surgery for gynecologic malignancy. This study aimed to evaluate the risk factors for lower limb lymphedema development in gynecologic cancer patients who underwent initial treatment.

Methods A retrospective cohort design was used to follow 903 gynecologic cancer patients who underwent treatment at Kurume University Hospital between January 1, 2013 and December 31, 2015. Data analyses were performed in 356 patients, and the patients were followed up until December 31, 2017. The model comprised two components to facilitate statistical model construction. Specifically, a discrete survival time model was constructed, and a complementary log–log link model was fitted to estimate the hazard ratio. Associations between risk factors were estimated using generalized structural models.

Results The median follow-up period was 1083 (range 3–1819) days, and 54 patients (15.2%) developed lower limb lymphedema, with a median onset period of 240 (range 3–1415) days. Furthermore, 38.9% of these 54 patients developed lower limb lymphedema within 6 months and 85.2% within 2 years. International Federation of Gynecology and Obstetrics stage, radiotherapy, and number of lymph node dissections (≥ 28) were significant risk factors.

Conclusion Simultaneous examination of the relationship between lower limb lymphedema and risk factors, and analysis among the risk factors using generalized structural models, enabled us to construct a clinical model of lower limb lymphedema for use in clinical settings to alleviate this condition and improve quality of life.

Keywords Lower limb lymphedema \cdot Risk factor \cdot Gynecologic cancer

Introduction
Most research on lower limb lymphedema (LLL) has been conducted in gynecologic cancer patients after surgery for gynecologic malignancy. Although studies on the causes of LLL in Japan and abroad have been conducted in recent years, research is still lagging compared to that on upper limb lymphedema \cite{1, 2}. Patients with LLL suffer psychological damage due to motor function disorders and physical handicapping and may develop severe complications, such as cellulitis, which significantly worsen quality of life (QOL).

In previous studies, postoperative radiotherapy \cite{3–13} and the number of lymph node (LN) dissections \cite{9, 10, 12–19} were recognized as risk factors for LLL; however, reported risk factors differ between studies \cite{20, 21}. Although lymphedema development appeared in a literature review, statistical analysis should simultaneously include the relationship between lymphedema onset and risk factors, and the relationship between risk factors, to determine the risk factors for lymphedema. To date, no study has included a prediction model including the relationship between risk factors \cite{1, 22}.

This study aimed to estimate the “survival curve” of LLL in gynecologic cancer patients after initial treatment using 5-year follow-up records, and to construct a clinical pathology model of LLL development based on structural equation...
modeling where risk factors associated with LLL incidence and clinically interpretable relationships between risk factors can be simultaneously examined.

Patients and methods

Study design and data source

A retrospective cohort design was used to follow-up 903 gynecologic cancer (cervical, endometrial, ovarian, and fallopian tube) patients who underwent treatment at the Kurume University Hospital Gynecology Department between January 1, 2013 and December 31, 2015. Finally, after a 3-year accrual period, data of 356 patients were used for analyses, and patients were followed up until December 31, 2017. Patients who underwent initial treatment for gynecologic cancer, including surgery, chemotherapy, radiotherapy, or any combination, were included. The exclusion criteria are described in Fig. 1.

The presence or absence and time of onset of LLL depended on the judgment of the attending physician. The physician in charge diagnosed LLL through physical examinations, including those for the presence of left-right difference in lower limb thickness. This study was conducted with the approval of the Kurume University Ethics Committee (number: 14063).

Risk factors

Data on 19 risk factors were obtained from hospital medical records; they were grouped into internal and external risk factors to facilitate the construction of statistical models, as shown in Table 1. Patients’ age and body mass index (BMI) were recorded at initial treatment.

Fig. 1 Subject selection and follow-up flow diagram

Statistical analysis

Risk factors were dichotomized to facilitate the interpretation of model parameters. Age was dichotomized with patients’ mean age value at initial treatment. BMI, an index of obesity, was dichotomized as ≥ 25 kg/m², using a clinically reasonable cut-off value. Cases were categorized according to the International Federation of Gynecology and Obstetrics (FIGO) guidelines into two categories by severity: stages I–II and stages III–IV. A tree model was applied as a method of binary conversion of LN clearance and the number of LNs dissected was categorized as ≥ 28 and < 28. In a previous study [8], 31 LN dissections were used as data cut-off values, and in this study, 28 or more were determined to be appropriate cutoff values. In clinical practice, LN biopsy or LN dissection is selected depending on the risk of cancer LN metastasis. Thus, the number of LN varies, depending on the location, but the number of LN dissections cannot be adjusted in each area. Therefore, the value for each LN area was set to two values that performed or not performed.

For univariate analysis, the Cox proportional hazard model was used to estimate the hazard ratio of each risk factor on the incidence rate of LLL. Multiple complex relationships between risk factors affect the incidence of LLL [1]. To model the complexity of LLL development, the structural equation modeling approach was employed to examine the impact of the risk factors. The model comprised components; the first one is the survival model which estimated the
hazard of risk factors, and the second one represented the complex relationship between risk factors. Specifically, the discrete survival time model was constructed by partitioning the follow-up period into 180-day intervals. Additionally, the complementary log–log link model [23] was fitted to estimate hazard ratio, while the association between risk factors was estimated using generalized structural models (GSEMs). The outline of the GSEM is described in the appendix. Data analysis was performed using the SAS 9.4 TS Level 1 M3 statistical software (SAS Institute Inc., NC, USA), JMP Pro13.2.1 (JMP is a product of SAS, located at A Campus Drive, Cray, NC, USA), Stata/MP 14.0 (StataCorp LP 4905 Lakeway Drive College Station, TX 77845 USA), and the R version 2.15.2 (The R Foundation for Statistical Computing, Vienna, Austria).

Results

Table 2 shows patient characteristics categorized by type of gynecologic cancer. All 356 patients were Japanese, with a mean age of 58.4 years (median 59.0 years; range 18–95 years) and mean BMI of 23.2 kg/m² (median 22.4 kg/m²; range 14.1–47.6 kg/m²). Mean age at first treatment (median, range) for cervical carcinoma, endometrial carcinoma, and ovarian cancer, including fallopian tube cancer, was 54.8 years (median 49 years; range 30–81 years), 61.6 years (median 59.5 years; range 44–86 years), and 57.7 years (median 60 years; range 46–83 years), respectively. FIGO for staging gynecological cancer was 63% during stage I (225 patients) and 17% during stage III (61 patients). The types of therapy were surgery (34 patients), chemotherapy and radiotherapy (29 patients), radiotherapy (18 patients), or surgery and radiotherapy (17 patients). Specifically, there are two types of radiotherapy: external beam irradiation and intracavitary brachytherapy. Endometrial or ovarian cancer is irradiated externally or with radiotherapy combined with external and intracavitary brachytherapy. External beam irradiation can irradiate the lesion, uterus, vagina, and pelvic LN area from outside the body. However, intracavitary brachytherapy can be performed by concentrating a high dose at the lesion site using a radiation source from the uterus or vagina, while suppressing the radiation dose of other organs. There are differences in the type of radiotherapy depending on the type of cancer, such as external beam irradiation for endometrial/ovarian cancer, and external beam irradiation after surgery or intracavitary brachytherapy combined with external beam irradiation. Although detailed data are not shown, differences in radiotherapy by cancer type were not found to directly affect the development of LLL (OR 0.79; \( p = 0.56 \)). External beam radiation was performed for the entire pelvis; total dose was 45–50.4 Gy (1.8 Gy, 25–28 Fr). Conversely, surgery and a combination of surgery and chemotherapy were performed on 90% of patients with endometrial and ovarian cancer.

The Kaplan–Meier survival curve is shown in Fig. 2 where the median follow-up period for 356 patients was 1083 days (range 3–1819 days). A total of 54 patients (15.2%) developed LLL with a median onset period of 240 days (range 3–1415 days). Furthermore, 38.9% of them developed LLL within 6 months and 85.2% within 2 years. In this study, the follow-up period was set from 720 to 1800 days, but LLL occurred 3 days after the first treatment. Also, seven out of 302 patients who did not develop LLL had a follow-up period of less than 100 days, for reasons such as transfer after initial treatment.

Table 3 shows the distribution of risk factors among patients with and without LLL. The hazard ratio for each risk factor was obtained from a univariate Cox proportional hazard model, and 95% confidence intervals are also shown in Table 3. FIGO stage (III–IV), radiotherapy, and number of LN dissections (≥ 28) were significant, with the level of significance being less than 5%. Generalized structure
equation modeling was employed to construct a clinical model as shown in Fig. 3. This clinical model consisted of two components. The first was a discrete time survival model to estimate the hazard ratio among risk factors. FIGO stage (HR 2.3; 95% CI 1.2–4.2), radiotherapy (HR 2.2; 95% CI 1.1–4.5), and the number of LNs dissected (≥ 28) (HR Table 2: Patient characteristics by type of gynecological cancer

| Characteristics                              | Cervical N=121 (34%) | Endometrial N=151 (42.4%) | Ovarian and tube N=84 (23.6%) | All N=356 (100%) |
|----------------------------------------------|----------------------|----------------------------|-------------------------------|------------------|
| **Age**a (year), mean±SD                    | 54.8 ± 15            | 61.6 ± 10.7                | 57.7 ± 14.8                   | 58.4 ± 13.6      |
| **BMI**b (kg/m²), mean±SD                   | 22.0 ± 4.0           | 24.7 ± 4.6                 | 21.9 ± 4.3                    | 23.2 ± 4.5       |
| **Stage (FIGO), n (%)**                      |                      |                            |                               |                  |
| I                                            | 73 (60%)             | 113 (75%)                  | 39 (47%)                      | 225 (63%)        |
| II                                           | 25 (21%)             | 7 (4%)                     | 11 (13%)                      | 43 (12%)         |
| III                                          | 13 (11%)             | 21 (14%)                   | 27 (32%)                      | 61 (17%)         |
| IV                                           | 10 (8%)              | 10 (7%)                    | 7 (8%)                        | 27 (8%)          |
| **Type of therapy, n (%)**                   |                      |                            |                               |                  |
| Sur only                                     | 34 (28%)             | 78 (52%)                   | 27 (33%)                      | 139 (39%)        |
| Chemo only                                   | 2 (2%)               | 0 (0%)                     | 1 (1%)                        | 3 (1%)           |
| Rad only                                     | 18 (15%)             | 0 (0%)                     | 0 (0%)                        | 18 (5%)          |
| Sur and Chemo                                | 14 (11%)             | 62 (41%)                   | 54 (64%)                      | 130 (36%)        |
| Chemo and Rad                                | 29 (24%)             | 1 (1%)                     | 1 (1%)                        | 31 (9%)          |
| Sur and Rad                                  | 17 (14%)             | 5 (3%)                     | 0 (0%)                        | 22 (6%)          |
| Sur and Chemo and Rad                        | 7 (6%)               | 5 (3%)                     | 1 (1%)                        | 13 (4%)          |
| **Number of LN resections**                  |                      |                            |                               |                  |
| Mean±SD                                      | 27.5 ± 15.7          | 22.8 ± 18.8                | 23.2 ± 20.5                   | 24.0 ± 18.7      |
| Min–Max                                      | 0–67                 | 0–88                       | 0–97                          | 0–97             |

Surgery, Chemotherapy, Rad radiotherapy, SD standard deviation, BMI body mass index, FIGO International Federation of Gynecology and Obstetrics, LN lymph node, Min minimum values, Max maximum values

aAt the time of initial treatment

bThe type of treatment is the treatment received between the initial treatment after the diagnosis of a gynecologic malignancy and the end of the follow-up after diagnosis of a gynecological malignancy and the end of follow-up

Fig. 2 Kaplan–Meier of plot of the cumulative incidence of lower limb lymphedema (LLL)

![Kaplan–Meier plot](image-url)
Table 3 Influence of factors on the absence or presence of lower limb lymphedema

| Variables                                      | Variable category | Absence (N=302 (84.8%)) | Presence (N=54 (15.2%)) | Hazard ratio 95% CI |
|------------------------------------------------|-------------------|--------------------------|--------------------------|---------------------|
| Age (years), n (%)                             | ≥ 58              | 168 (55.6)               | 30 (55.6)                | 0.59–1.73           |
|                                                | < 58 [reference]  | 134 (44.4)               | 24 (44.4)                |                     |
| BMI (kg/m²), n (%)                             | ≥ 25              | 86 (28.5)                | 13 (24.1)                | 0.44–1.54           |
|                                                | < 25 [reference]  | 216 (71.5)               | 41 (75.9)                |                     |
| Medical history and complication
| a, n (%)                                      | Yes               | 112 (37.5)               | 15 (27.8)                | 0.38–1.25           |
|                                                | No [reference]    | 187 (62.5)               | 39 (72.2)                |                     |
| Family history, n (%)                          | Yes               | 56 (18.5)                | 9 (16.7)                 | 0.44–1.84           |
|                                                | No [reference]    | 246 (81.5)               | 45 (83.3)                |                     |
| Pregnancy
| a, n (%)                                      | Yes               | 249 (83.3)               | 42 (77.8)                | 0.37–1.33           |
|                                                | No [reference]    | 50 (16.7)                | 12 (22.2)                |                     |
| Stage (FIGO), n (%)                            | III–IV            | 66 (21.9)                | 22 (40.7)                | 1.42–4.20           |
|                                                | I–II [reference]  | 236 (78.2)               | 32 (59.3)                |                     |
| Type of cancer, n (%)                          | Cervical          | 100 (33.1)               | 21 (38.9)                | 0.51–1.91           |
|                                                | Endometrial       | 133 (44.0)               | 18 (33.3)                | 0.33–1.31           |
|                                                | Ovarian and tube  | 69 (22.9)                | 15 (27.8)                |                     |
|                                                | [reference]       |                         |                         |                     |
| Surgery, n (%)                                 | Yes               | 260 (86.1)               | 44 (81.5)                | 0.35–1.38           |
|                                                | No [reference]    | 42 (13.9)                | 10 (18.6)                |                     |
| Chemotherapy, n (%)                            | Yes               | 153 (50.7)               | 24 (44.4)                | 0.45–1.32           |
|                                                | No [reference]    | 149 (49.3)               | 30 (55.6)                |                     |
| Radiotherapy, n (%)                            | Yes               | 65 (22.0)                | 19 (35.2)                | 1.09–3.35           |
|                                                | No [reference]    | 237 (78.0)               | 35 (64.8)                |                     |
| Type of therapy, n (%)                         | Combination therapy | 166 (55.0)            | 31 (57.4)                | 0.57–1.67           |
|                                                | Monotherapy       | 136 (45.0)               | 23 (42.6)                |                     |
| Type of surgery
| a, n (%)                                      | Total hysterectomy | 177 (76.3)            | 29 (76.3)                | 0.12–6.55           |
|                                                | Modified radical hysterectomy | 8 (3.5)             | 2 (5.3)                  | 0.11–13.14          |
|                                                | Radical hysterectomy | 42 (18.1)            | 6 (15.8)                 | 0.09–6.28           |
|                                                | Others [reference] | 5 (2.2)                 | 1 (2.6)                  |                     |
| Inguinal LN dissection, n (%)                  | Yes               | 137 (52.7)               | 29 (65.9)                | 0.87–3.04           |
|                                                | No [reference]    | 123 (47.3)               | 15 (34.1)                |                     |
| Pelvic LN biopsy, n (%)                        | Yes               | 52 (20)                  | 6 (13.6)                 | 0.28–1.58           |
|                                                | No [reference]    | 208 (80)                 | 38 (86.4)                |                     |
| Pelvic LN dissection, n (%)                    | Yes               | 166 (63.8)               | 34 (77.3)                | 0.86–3.53           |
|                                                | No [reference]    | 94 (36.2)                | 10 (22.7)                |                     |
| Para-aortic LN biopsy, n (%)                   | Yes               | 94 (36.2)                | 16 (36.4)                | 0.53–1.79           |
|                                                | No [reference]    | 166 (63.9)               | 28 (63.6)                |                     |
| Para-aortic LN dissection, n (%)               | Yes               | 68 (26.2)                | 15 (34.1)                | 0.75–2.60           |
|                                                | No [reference]    | 192 (73.9)               | 29 (65.9)                |                     |
| Number of LN dissection
| a, n (%)                                      | ≥ 28              | 95 (36.8)                | 25 (56.8)                | 1.14–3.77           |
|                                                | < 28 [reference]  | 163 (63.2)               | 19 (43.2)                |                     |
| LN metastasis                                  | Positive          | 41 (15.8)                | 11 (25.0)                | 0.89–3.49           |
|                                                | Negative [reference] | 219 (84.2)            | 33 (75.0)                |                     |

Total hysterectomy is the routine procedure for endometrial cancer, ovarian cancer, severe dysplasia, or invasive cervical cancer stage IA1. Bilateral oophorectomy is usually performed. Also, pelvic or para-aortic lymph node dissection is also performed. Depending on the status of the disease, para-aortic lymph node dissection may or may not be performed.

Modified radical hysterectomy is the routine procedure for stage IA2 invasive cervical cancer. It is positioned between total and radical hysterectomy. Bilateral oophorectomy is usually performed. Pelvic or para-aortic lymph node dissection may or may not be performed depending on the status of the disease.

Radical hysterectomy is the routine procedure for stage IB2 invasive cervical cancer. It involves the removal of the uterus, cervix, and the upper one-third of the vagina along with the cardinal ligament. Additionally, pelvic lymph node dissection and biopsy of para-aortic lymph nodes must be performed. Bilateral oophorectomy is usually performed.

aData missing: n (%) → 3 (1%)

bData missing: n (%) → 34 (11.2%)

cData missing: n (%) → 2 (1%)
1.9; 95% CI 1.0–3.5) were found to be significant risk factors for LLL development. Cancer types, inguinal LN dissection, pelvic LN dissection, para-aortic LN dissection, and LN metastasis have an indirect effect on the onset of LLL and have no direct effects.

The relationships between risk factors were modeled in the second component. Since all endogenous risk factors were binary, as shown in Fig. 3, logistic regression models were used to evaluate the interrelationship among risk factors. Standard treatment for each gynecologic malignant tumor includes surgery, chemotherapy, radiotherapy, or any combination, as shown in Table 2. Thus, although standard therapy differs depending on the type of cancer, the results in Table 3 indicate that cancer type has no influence on LLL. The odds of receiving radiotherapy were 42.4 times higher in patients with cervical cancer than in patients with other types of cancer (95% CI 29.5–60.9). Similarly, the odds of receiving radiotherapy were 6.4 times higher among patients with FIGO stages III–IV than in those with stages I–II (95% CI 4.4–9.3). Table 3 shows the incidence of LLL at LN excision sites was 17.5% (29/166) in patients with inguinal LN dissection (95% CI 0.87–3.04), 17% (34/200) in patients with pelvic LN dissection (95% CI 0.86–3.53), and 18% (15/83) in patients with para-aortic LN dissection (95% CI 0.75–2.60). However, as shown in Table 4, the probability of removing each LN with 28 or more LN resections compared to less than 28 is 5.9 times higher with inguinal LN (95% CI 4.4–8.0). It is 4.0 times higher in pelvic LN (95% CI 2.7–5.9) and 2.8 times higher in para-aortic LN (95% CI 2.1–3.6). Similarly, patients with cervical cancer were 1.6 times more likely than patients with non-cervical cancer to have 28 or more LN resections (95% CI 1.3–2.1). There was no difference in the incidence of LLL by individual site, but it was higher in cases of 28 or more. Total LN dissections indicates the intensity (thoroughness) of the dissection, and it was confirmed that inguinal LN dissection was performed in cases where thorough dissection was required. A high proportion of LLL was observed when inguinal LN dissection was performed indirectly. Other odds ratios are shown in Table 4. All parameter estimates in Table 4 were obtained simultaneously based on GSEM.

Discussion

The accumulation of scientific information on the developmental history of LLL has been delayed because priority was given to treating gynecological cancer. Hence, this study mainly focused on reporting the incidence of LLL development and its clinical risk factors based on sound scientific methods. This study differs from previous reports in that the risk factors for LLL development in patients treated for gynecologic cancer (cervical cancer, endometrial cancer, and ovarian cancer including fallopian tube cancer) were examined without limiting the treatment method. Although there are differences in standard treatment depending on the type of cancer, the results of the univariate analysis did not directly affect the occurrence of LLL according to type of cancer. Therefore, we analyzed the risk factors directly related to LLL occurrence, regardless of the type of cancer.
As a result, the number of LNs dissected (≥ 28) was a significant risk factor for LLL development regardless of site and extent of LN dissection. Nine out of 54 cases of LLL showed recurrence. However, the relationship between recurrence as a pelvic mass and occurrence of LLL could not be denied in only one case of recurrence. Therefore, globally, it can be presumed that the occurrence of LLL is due to treatment. This result supports the notion that sentinel LN biopsies result in lower incidence of LLL by not performing unnecessary LN dissections. Sentinel LN is defined as a LN where cancer cells reach LN metastasis through the tumor and the lymph vessel connected to it. Therefore, if cancer metastasis has not occurred in the sentinel LN, it is believed that there is a high possibility that it has not spread to other LNs, and there is no other metastasis. Therefore, to reduce the number of LN resections recognized as a risk factor for the development of LLL less than 28, the presence of metastasis to sentinel LNs [24, 25] is confirmed, and the significance of dissection biopsy is high. In the future, sentinel LN biopsy should be actively introduced to reduce the incidence of LLL. According to the literature, there are limited records of patients after surgery. Although there are reports on the incidence and timing of postoperative LLL, there is no clear report on the incidence and timing of LLL in gynecologic cancer treatment after initial treatment, including treatments other than surgery. Previous studies [3, 6, 9–21] have reported postoperative radiotherapy and the number of LN dissections as risk factors for LLL. However, some studies have reported that the location of the LN is a risk factor. For example, Kuroda et al. [4] studied pelvic lymphadenectomy (PLA) in patients with or without para-aortic lymphadenectomy (PALA) and reported BMI (≥ 25), PLA + PALA, and postoperative radiation therapy as the risk factors. In contrast, Ohba et al. [6] reported that suprafemoral node dissection and postoperative radiation therapy are risk factors for the development of LLL. However, a study on postoperative cervical cancer patients reported that pelvic and para-aortic lymphadenectomy and the number of LNs are not risk factors. Todo et al. [8] examined the effect of removing circumflex iliac nodes up to the distal external iliac nodes.

| Component 1 outcome (time to event) | Coefficient | Hazard ratio | 95% CI | p value |
|------------------------------------|-------------|--------------|--------|---------|
| Direct effect of “lymphedema onset” |             |              |        |         |
| FIGO (III–IV)                      | 0.824       | 2.3          | 1.2–4.2| 0.009   |
| Radiotherapy (performed)           | 0.804       | 2.2          | 1.1–4.5| 0.027   |
| Number of LN dissection (≥ 28)     | 0.64        | 1.9          | 1.0–3.5| 0.037   |
| Component 2 outcome (yes/no)       |             |              |        |         |
| Direct effect of “FIGO stage (III–IV)” |           |              |        |         |
| LN metastasis (positive)           | 2.722       | 15.2         | 11.4–20.2| <0.001  |
| Direct effect of “Radiotherapy (performed)” |           |              |        |         |
| Type of cancer (cervical cancer)   | 3.748       | 42.4         | 29.5–60.9| <0.001  |
| FIGO (III–IV)                      | 1.854       | 6.4          | 4.4–9.3| <0.001  |
| Direct effect of “Number of LN resection (≥ 28)” |       |              |        |         |
| Inguinal LN dissection (+)         | 1.783       | 5.9          | 4.4–8.0| <0.001  |
| Pelvic LN dissection (+)           | 1.396       | 4.0          | 2.7–5.9| <0.001  |
| Para-aortic LN dissection (+)      | 1.012       | 2.8          | 2.1–3.6| <0.001  |
| Type of cancer (cervical cancer)   | 0.467       | 1.6          | 1.3–2.1| <0.001  |

*LN lymph node, FIGO International Federation of Gynecology and Obstetrics, CI confidence interval*
(CINDEIN) in patients with uterine corpus malignancies. It was reported that adjuvant radiation therapy, resection of more than 31 LN, and removal of CINDEIN are risk factors for the development of LLL. These findings were mainly based on postoperative patients who received limited and specific treatment. Unlike previous studies, this study included all patients who received initial treatment for gynecologic cancer, regardless of surgery. This includes patients who had been treated with chemotherapy or radiation therapy and who had not undergone surgery. Therefore, it is speculated that lymphadenectomy did not directly affect the development of LLL.

As shown in Table 2, although the maximum number of LN dissections in cervical cancer is small, compared to those in endometrial cancer and ovarian cancer, the average number of LN dissections in cervical cancer was higher than that in cervical cancer and ovarian cancer. The reason is that pelvic LN dissection is usually performed in cervical cancer, but in endometrial/ovarian cancer, pelvic LN dissection or para-aortic LN dissection may not be performed for low-risk patients who do not have cancer metastasis at each LN site. In some cases, LN dissection was omitted, and only LN biopsy was performed, and the reason for this study may be that there were many low-risk patients with endometrial/ovarian cancer. LN biopsy randomly collects one or two LNs to see if there is cancer LN metastasis. However, LN dissection is performed when the cancer is likely to have spread to it as the LNs in the cancerous area are removed for the purpose of preventing recurrence; the number of LN dissection inevitably increases. As shown in Table 3, LN excision and cancer type at each site did not directly affect the onset of LLL. However, as shown in Table 4, when each LN excision site and cancer type had 28 or more LN excisions it had an indirect effect on LLL. Although detailed data are not shown here, differences in surgery by cancer type were not found to directly affect the development of LLL.

In this study, the risk factors directly affecting LLL development were FIGO progression stage (III–IV), number of LNs dissected (≥ 28), and radiotherapy (performed). Simultaneous examination of the relationship between LLL and risk factors, and among the risk factors using GSEM, enabled us to construct a clinical model of LLL development, which can be used in the clinical setting. It will also provide information to alleviate the incidence of LLL and improve patient QOL.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Appendix: Fitting the cox proportional hazard model via the generalized structural equation model

Let $T_i$ be onset time of lymphedema for $i$th patient ($i = 1, \ldots, n$). Onset time is interval censored if we only know event occurred within time interval $\tau_{r-1} < T_i \leq \tau_r (r = 1, \ldots, m)$. If event or censoring occurred in time interval $a$, hazard function $h(a)$ for $i$-th subject is defined as $h(a) = P(T_i = a | T_i > a_i - 1)$.

Then, $i$th subject’s contribution to the likelihood, $L_i$, is

$$L_i = \prod_{r=1}^{a_i} h(r)^{Y_{ir}} (1 - h(r))^{1-Y_{ir}}$$

$Y_{ir}$ is an indicator variable defined as $Y_{ir} = 0$ if $r < a_i$ and $Y_{ir} = \delta_i$ if $r = a_i$ where $\delta_i$ is censoring indicator (= 1 if onset lymphedema, otherwise = 0).

It can be shown that $\log \{ - \log h(r|X_i) \} = \alpha_r + X'_i\beta$ if we assume proportional hazard model $h(r|X_i) = h_0(r) \exp(X'_i\beta)$ where $X_i$ is a vector of risk factors,
\[ \alpha_r = \log \left( \log S_0(r) - \log S_0(r-1) \right) \text{ and } S_0(r) = \text{baseline survival function} \ [28, 29]. \]

Let \( \mu_{ir} \) be expectation of \( Y_{ir} \), \( E(Y_{ir}) = \mu_{ir}^{(Y)} \), then survival analysis of lymphedema is modeled as \( g_1(\mu_{ir}^{(Y)}) = \alpha_r + X_i^T \beta \) where \( g_1 \) is complimentary log–log link function.

Effect of exogenous risk factor \( W_i \) on endogenous risk factors \( X_i \) will be modeled as \( g_2(\mu_{ir}^{(X)}) = \gamma^T W_i \) where \( \mu_{ir}^{(X)} \) is mean vector of \( X_i \), and \( g_2 \) is an appropriate link function for \( X_i \). \( \{ g_1(\mu_{ir}^{(Y)}), g_2(\mu_{ir}^{(X)}) \} \) are simultaneously modeled under generalized structural equation models [30].

References

1. Kimura E (2013) A literature review about risk factor of lymphoedema. Lymph RAP 1:5–24
2. Biglia N, Zanfagnin V, Daniele A et al (2017) Lower body lymphedema in patients with gynecologic cancer. Anticancer Res 37:4005–4015
3. Akita S, Mitsukawa N, Rikihisa N et al (2013) Early diagnosis and risk factors for lymphedema following lymph node dissection for gynecologic cancer. Plast Reconstr Surg 131:283–290
4. Kuroda K, Yamamoto Y, Yanagisawa M et al (2017) Risk factors and a prediction model for lower limb lymphedema following lymphadenectomy in gynecologic cancer: a hospital-based retrospective cohort study. BMC Womens Health 17:50
5. Kim JH, Choi JH, Ki EY et al (2012) Incidence and risk factors of lower extremity lymphedema after radical surgery with or without adjuvant radiotherapy in patients with FIGO stage I to stage II A cervical cancer. Int J Gynecol Cancer 22:686–691
6. Obha Y, Todo Y, Kobayashi N et al (2011) Risk factors for lower-limb lymphedema after surgery for cervical cancer. Int J Clin Oncol 16:238–243
7. Beesley V, Janda M, Eakin E et al (2007) Lymphedema after gynecological cancer treatment: prevalence, correlates, and supportive care needs. Cancer 109(12):2607–2614
8. Todo Y, Yamazaki H, Takeshita S et al (2015) Close relationship between removal of circumflex iliac nodes to distal external iliac nodes and postoperative lower-extremity lymphedema in uterine corpus malignant tumors. Gynecol Oncol 139:160–164
9. Beesley VL, Rowlands IJ, Hayes SC et al (2015) Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. Gynecol Oncol 136:87–93
10. Yost KJ, Cheville AL, Al-Hilli MM et al (2014) Lymphedema after surgery for endometrial cancer: prevalence, risk factors, and quality of life. Obstet Gynecol 124:307–315
11. Todo Y, Yamamoto R, Minobe S et al (2010) Risk factors for postoperative lower-extremity lymphedema in endometrial cancer survivors who had treatment including lymphadenectomy. Gynecol Oncol 119:60–64
12. Tada H, Teramukai S, Fukushima M et al (2009) Sasaki H: Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma. BMC Cancer 9:47
13. Hayes SC, Janda M, Ward LC et al (2017) Lymphedema following gynecological cancer: results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors. Gynecol Oncol 146:623–629
14. Halaska MJ, Novackova M, Malu I et al (2010) A prospective study of postoperative lymphedema after surgery for cervical cancer. Int J Gynecol Cancer 20:900–904
15. Fuller J, Guderian D, Kohler C et al (2008) Lymph edema of the lower extremities after lymphadenectomy and radiotherapy for cervical cancer. Strahlenther Onkol 184:206–211
16. Mendivil AA, Rettenmaier MA, Abaid LN et al (2016) Lower-extremity lymphedema following management for endometrial and cervical cancer. Surg Oncol 25:200–204
17. Abu-Rustum NR, Alektiar K, Lasonos A et al (2006) The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 103:714–718
18. Ki EY, Park JS, Lee KH et al (2016) Incidence and risk factors of lower extremity lymphedema after gynecologic surgery in ovarian cancer. Int J Gynecol Cancer 26:1327–1332
19. Mitra D, Catalano PJ, Cimak N et al (2017) The risk of lymphedema after postoperative radiation therapy in endometrial cancer. J Gynecol Oncol 27:e4
20. Hopp EE, Osborne JL, Schneider DK et al (2016) A prospective pilot study on the incidence of post-operative lymphedema in women with endometrial cancer. Gynecol Oncol Rep 15:25–28
21. Achouri A, Huchon C, Bats AS et al (2013) Complications of lymphadenectomy for gynecologic cancer. Eur J Surg Oncol 39:81–86
22. Kunitake T, Kakuma T, Ushijima K (2018) Lymphedema development in the lower extremities of patients with gynecological malignancies. J Lymphedema Res 1:39–46
23. Lin JH, Lee WC (2016) Complementary log regression for sufficient-cause modeling of epidemiologic data. Sci Rep 6:39023
24. Bodurtha Smith AJ, Fader AN, Tanner EJ (2017) Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol 216:459–466
25. Wang T, Hu Y, He Y et al (2019) A retrospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Arch Gynecol Obstet 299:1429–1435
26. Graf N, Rubtchik K, Schmidt AM et al (2013) Frequency and risk factors of lower limb lymphedema following lymphadenectomy in patients with gynecological malignancies. Eur J Gynaecol Oncol 34:23–27
27. Hareyama H, Hada K, Goto K et al (2015) Prevalence, classification, and risk factors for postoperative lower extremity lymphedema in women with gynecological malignancies: a retrospective study. Int J Gynecol Cancer 25:751–757
28. Rabe-Hesketh S, Skrondal A (2005) Multilevel and longitudinal modeling using stata, 2nd edn. Stata Press, College Station
29. Thompson WA (1977) On the treatment of grouped observations in life studies. Biometrics 33:463–470
30. STATA Structural Equation Modeling Reference manual release 13 https://www.stata.com/manuals13/sem.pdf. Accessed 1 Sept 2018

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.